Azithromycin Monohydrate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Azithromycin Monohydrate: Drug Repurposing Evaluation Report
One-Sentence Summary
Azithromycin is a widely-used macrolide antibiotic registered in Malaysia for the treatment of bacterial infections. The TxGNN model did not generate any predicted new indications for this drug in the current analysis run. As a result, there is no repurposing candidate to evaluate at this time, and significant data gaps remain in the evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (license details missing) |
| Predicted New Indication | None — no predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No predictions or supporting studies) |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
There is no TxGNN prediction to evaluate for Azithromycin Monohydrate. The predicted_indications array in the evidence pack is empty, meaning the model either did not find high-confidence repurposing candidates or the drug was not successfully mapped into the knowledge graph.
Azithromycin is a well-known macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is commonly prescribed for respiratory tract infections, skin and soft tissue infections, sexually transmitted infections, and otitis media. However, this mechanism of action information was not included in the evidence pack (listed as a data gap), and no DrugBank ID was provided, which may have contributed to the lack of predictions.
Without a successful DrugBank mapping (drugbank_id is null), the TxGNN knowledge graph cannot link this drug to its known pharmacological targets and disease associations, making it impossible to generate repurposing predictions. Resolving the DrugBank mapping is a prerequisite before re-running the prediction pipeline.
Clinical Trial Evidence
Currently no related clinical trials to report, as no new indication was predicted.
Literature Evidence
Currently no related literature to report, as no new indication was predicted.
Malaysia Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| (Not provided) | (Not provided) | (Not provided) | (Not provided) |
| (Not provided) | (Not provided) | (Not provided) | (Not provided) |
| (Not provided) | (Not provided) | (Not provided) | (Not provided) |
| (Not provided) | (Not provided) | (Not provided) | (Not provided) |
Note: 4 registrations were found via NPRA query (query date: 2026-03-27), but the license detail fields (authorization number, product name, dosage form, approved indication) were not populated in the evidence pack. This data gap needs to be resolved by re-querying the NPRA database.
Safety Considerations
Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, and drug interactions) are currently missing from the evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: No repurposing candidates were generated by TxGNN for Azithromycin Monohydrate. The evidence pack contains critical data gaps — most importantly, the missing DrugBank ID (which prevents knowledge graph integration) and empty license/indication details from NPRA. Without these foundational data, it is not possible to conduct a meaningful repurposing evaluation.
To proceed, the following is needed:
- DrugBank ID mapping — Azithromycin’s DrugBank ID is likely
DB00207. This must be confirmed and populated so the drug can be linked into the TxGNN knowledge graph. - NPRA license details — Re-query the NPRA database to retrieve full registration details (authorization numbers, product names, dosage forms, approved indications) for all 4 registrations.
- Mechanism of action (MOA) — Retrieve from DrugBank once the ID is mapped (macrolide antibiotic, 50S ribosomal subunit inhibitor).
- Safety data — Download and parse the package insert(s) to extract key warnings, contraindications, and drug interaction information.
- Re-run TxGNN prediction — After resolving the DrugBank mapping, re-execute the knowledge graph and deep learning prediction pipeline to generate repurposing candidates.
This report is for research reference only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.